From Our 2013 Archives
Implanted Device Approved to Decrease Seizures
Latest Neurology News
FRIDAY, Nov. 15, 2013 (HealthDay News) -- A device implanted within the skull to help reduce the frequency of epileptic seizures has been approved by the U.S. Food and Drug Administration.
Epilepsy, estimated to affect nearly 3 million people in the United States, is the third most common neurological disorder behind Alzheimer's disease and stroke. Some 40 percent of those treated for epilepsy continue to have seizures, the FDA said.
Approval for the new device was based on clinical studies involving 191 people with drug-resistant epilepsy. Three months after the device was implanted, participants had about 38 percent fewer seizures per month compared to a 17 percent decrease in seizures among people who had the implanted device turned off, the FDA said. The most common adverse reactions included implant site infection and premature battery discharge.
The RNN Stimulator is produced by Neurospace Inc., based in Mountain View, Calif.
-- Scott Roberts
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions